PROFILPELAJAR.COM

11β-甲基-19-去甲睾酮十二烷基碳酸酯
臨床資料
其他名稱	11β-MNTDC; CDB-4754
给药途径	口服, 肌肉注射
藥物類別（英语：Drug class）	雄激素; 蛋白同化甾类; 雄激素酯; 孕激素
识别信息
	IUPAC命名法 [(8R,9S,10R,11S,13S,14S,17S)-11,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] dodecyl carbonate; ;
CAS号	904901-01-5
PubChem CID	68648455;
ChemSpider	52085304;
UNII	906T1U911E;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID701168521 ;
化学信息
化学式	C32H52O4
摩尔质量	500.76 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES CCCCCCCCCCCCOC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](C)C[C@]12C;
	InChI InChI=1S/C32H52O4/c1-4-5-6-7-8-9-10-11-12-13-20-35-31(34)36-29-19-18-28-27-16-14-24-21-25(33)15-17-26(24)30(27)23(2)22-32(28,29)3/h21,23,26-30H,4-20,22H2,1-3H3/t23-,26-,27-,28-,29-,30+,32-/m0/s1; Key:JVTCGMMASZPYDR-UIRZMXPTSA-N;

11β-甲基-19-去甲睾酮十二烷基碳酸酯^[1]（英語：11β-Methyl-19-nortestosterone 17β-dodecylcarbonate，药物开发代码：CDB-4754），简称11β-MNTDC 。是一种合成的口服蛋白同化甾类药物，为19-去甲睾酮的衍生物。由美国国家儿童健康与人类发育研究所（NICHD）所开发，目前尚未上市的药物^[2]^[3]^[4]^[5]。其为雄激素酯衍生物，是11β-甲基-19-去甲睾酮（英语：11β-Methyl-19-nortestosterone）（11β-MNT）与十二烷基碳酸形成的酯，同时也是11β-MNT的前体药物^[2]^[3]^[4]^[5]。

11β-MNTDC与其姊妹药物十一酸二甲雄酮（英语：Dimethandrolone undecanoate）（DMAU）共同作为一种男性口服避孕药被同期开发^[6]^[7]^[8]。

相比于睾酮，11β-MNTDC不会被5α还原酶代谢，所以雄激素性脱发程度较低^[9]。

参考文献

^ 两款男性口服避孕药已经通过了Ⅰ期临床试验. 上海医药. 2022, 43 (13): 58 [2024-07-05]. （原始内容存档于2024-12-11）.
^ ^2.0 ^2.1 Attardi BJ, Marck BT, Matsumoto AM, Koduri S, Hild SA. Long-term effects of dimethandrolone 17β-undecanoate and 11β-methyl-19-nortestosterone 17β-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. Journal of Andrology. 2011, 32 (2): 183–192. PMID 20798389. doi:10.2164/jandrol.110.010371 .
^ ^3.0 ^3.1 Attardi BJ, Hild SA, Koduri S, Pham T, Pessaint L, Engbring J, et al. The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects. The Journal of Steroid Biochemistry and Molecular Biology. October 2010, 122 (4): 212–218. PMC 2949447 . PMID 20599615. doi:10.1016/j.jsbmb.2010.06.009.
^ ^4.0 ^4.1 Hild SA, Attardi BJ, Koduri S, Till BA, Reel JR. Effects of synthetic androgens on liver function using the rabbit as a model. Journal of Andrology. 2010, 31 (5): 472–481. PMC 2943539 . PMID 20378929. doi:10.2164/jandrol.109.009365.
^ ^5.0 ^5.1 US 7820642,Blye RP, Kim HK,「Nandrolone 17β-carbonates」,发行于26 October 2010,指定于U.S. Department of Health and Human Services
^ Thirumalai A, Page ST. Recent Developments in Male Contraception. Drugs. January 2019, 79 (1): 11–20. PMID 30588563. S2CID 56895132. doi:10.1007/s40265-018-1038-8.
^ Second potential male birth control pill passes human safety tests. [2024-07-05]. （原始内容存档于2019-04-11）.
^ Yuen F, Thirumalai A, Pham C, Swerdloff RS, Anawalt BD, Liu PY, Amory JK, Bremner WJ, Dart C, Wu H, Hull L, Blithe DL, Long J, Wang C, Page ST. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. The Journal of Clinical Endocrinology and Metabolism. March 2020, 105 (3): e835–e847. PMC 7049261 . PMID 31976519. doi:10.1210/clinem/dgaa032.
^ Shapiro LJ, Shapiro DB. Low Anabolic Profile in Assessing a Patient's Overall Hair Loss. 2018: 687–698. ISBN 978-4-431-56545-1. doi:10.1007/978-4-431-56547-5_72.